Azenosertib is a small molecule commercialized by Zentalis Pharmaceuticals, with a leading Phase II program in Uterine Cancer. According to Globaldata, it is involved in 18 clinical trials, of which 10 are ongoing, 6 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Azenosertib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Azenosertib is expected to reach an annual total of $94 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Azenosertib Overview

Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed or refractory osteosarcoma, platinum sensitive ovarian cancer, fallopian tube, peritoneal carcinoma, pancreatic cancer, recurrent uterine serous carcinoma (USC), metastatic colorectal cancer, platinum resistant ovarian cancer, PARPi resistant ovarian cancer, glioblastoma multiforme, triple-negative breast cancer, HER2-negative breast cancer, relapsed, refractory and secondary acute myeloid leukemia. It is administered orally as a tablet. The drug candidate acts by targeting WEE1.

It was also under development for the treatment of metastatic advanced breast cancer and non-small cell lung carcinoma.

Zentalis Pharmaceuticals Overview

Zentalis Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs to treat cancers. Its lead product candidate is ZN-c3, a WEE1 inhibitor against uterine serous carcinoma, solid tumors, osteosarcoma and ovarian cancer. The company is also evaluating ZN-c5, an oral SERD (selective estrogen receptor degrader) for the treatment of breast cancer; ZN-d5, a BCL-2 (B-cell lymphoma 2) inhibitor targeting hematologic malignancies; and ZN-e4, an EGFR (epidermal growth factor receptor) inhibitor to treat non-small cell lung carcinoma. It works in collaboration with Pfizer Inc, Mayo Clinic and SciClone Pharmaceuticals Inc, among others. Zentalis Pharmaceuticals is headquartered in New York, the US.
The operating loss of the company was US$299.5 million in FY2023, compared to an operating loss of US$227.3 million in FY2022. The net loss of the company was US$292.2 million in FY2023, compared to a net loss of US$236.8 million in FY2022.

For a complete picture of Azenosertib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.